Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints [Yahoo! Finance]
McKesson Corporation (MCK)
Last mckesson corporation earnings: 2/4 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.mckesson.com
Company Research
Source: Yahoo! Finance
Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 ( GLP-1 ) receptor agonist, in Chinese adults with obesity (GLORY-2) met the primary endpoints and all key secondary endpoints. Innovent plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term. GLORY-2 (NCT06164873) is a Phase 3 clinical study to evaluate the efficacy and safety of mazdutide 9 mg combined with lifestyle intervention versus placebo in Chinese adults with obesity (BMI =30 kg/m²). The study enrolled 462 participants (including 16% with type 2 diabetes), rand
Show less
Read more
Impact Snapshot
Event Time:
MCK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCK alerts
High impacting McKesson Corporation news events
Weekly update
A roundup of the hottest topics
MCK
News
- McKesson (NYSE:MCK) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- McKesson (NYSE:MCK) had its "buy (a-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- McKesson Corporation (MCK) Strong Quarter Spurs Analyst Confidence [Yahoo! Finance]Yahoo! Finance
- McKesson (NYSE:MCK) had its "buy (b+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- McKesson (NYSE:MCK) had its price target raised by analysts at Wells Fargo & Company from $816.00 to $914.00. They now have an "equal weight" rating on the stock.MarketBeat
MCK
Earnings
- 11/5/25 - Beat
MCK
Sec Filings
- 11/17/25 - Form 25-NSE
- 11/10/25 - Form 4
- 11/6/25 - Form 10-Q
- MCK's page on the SEC website